Literature DB >> 9593023

Naive human T cells develop into Th1 or Th0 effectors and exhibit cytotoxicity early after stimulation with Leishmania-infected macrophages.

D M Russo1, P Chakrabarti, J M Burns.   

Abstract

Studies of human disease suggest that naturally acquired immunity is the predominant outcome of Leishmania infection. Normally protective immune mechanisms activated during asymptomatic or self-healing infections may be minimal in patients who develop disease. To explore early immune responses, an in vitro model of human Leishmania infection was developed in which naive T cells were sensitized with Leishmania-infected macrophages. An analysis of Leishmania-specific cytokine production by these T cell lines revealed that most individuals developed Th1 or Th0 responses early after infection. Infected macrophages from Th1 responders produced interleukin-12. Th0 responders who produced little or no endogenous interleukin-12 could be converted to the Th1 phenotype by addition of interleukin-12 during priming. Finally, infection-sensitized T cells specifically lysed Leishmania-infected macrophages. Thus, this in vitro model system can be used to delineate protective human immune responses against Leishmania induced early after infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9593023     DOI: 10.1086/515284

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

1.  Virulent or avirulent (dhfr-ts-) Leishmania major elicit predominantly a type-1 cytokine response by human cells in vitro.

Authors:  C Brodskyn; S M Beverley; R G Titus
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

2.  Combined Immunotherapy With Belatacept and BTLA Overexpression Attenuates Acute Rejection Following Kidney Transplantation.

Authors:  Hengcheng Zhang; Zijie Wang; Jiayi Zhang; Zeping Gui; Zhijian Han; Jun Tao; Hao Chen; Li Sun; Shuang Fei; Haiwei Yang; Ruoyun Tan; Anil Chandraker; Min Gu
Journal:  Front Immunol       Date:  2021-02-24       Impact factor: 7.561

3.  Naive human T cells develop into Th1 effectors after stimulation with Mycobacterium tuberculosis-infected macrophages or recombinant Ag85 proteins.

Authors:  D M Russo; N Kozlova; D L Lakey; D Kernodle
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

4.  Differences in gamma interferon production in vitro predict the pace of the in vivo response to Leishmania amazonensis in healthy volunteers.

Authors:  M M Pompeu; C Brodskyn; M J Teixeira; J Clarêncio; J Van Weyenberg; I C Coelho; S A Cardoso; A Barral; M Barral-Netto
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

5.  Characterization of the T-cell receptor Vbeta repertoire in the human immune response against Leishmania parasites.

Authors:  Jorge Clarêncio; Camila I de Oliveira; Glória Bomfim; Margarida M Pompeu; Maria Jania Teixeira; Theolis C Barbosa; Sebastião Souza-Neto; Edgar M Carvalho; Cláudia Brodskyn; Aldina Barral; Manoel Barral-Netto
Journal:  Infect Immun       Date:  2006-08       Impact factor: 3.441

6.  Leishmania infantum leishmaniasis in corticosteroid--treated patients.

Authors:  Silvia Pittalis; Emanuele Nicastri; Francesco Spinazzola; Piero Ghirga; Michele De Marco; Maria Grazia Paglia; Pasquale Narciso
Journal:  BMC Infect Dis       Date:  2006-12-18       Impact factor: 3.090

7.  Nivolumab Enhances In Vitro Effector Functions of PD-1+ T-Lymphocytes and Leishmania-Infected Human Myeloid Cells in a Host Cell-Dependent Manner.

Authors:  Christodoulos Filippis; Katharina Arens; Gaetan Aime Noubissi Nzeteu; Gabriele Reichmann; Zoe Waibler; Peter Crauwels; Ger van Zandbergen
Journal:  Front Immunol       Date:  2017-12-22       Impact factor: 7.561

8.  Lutzomyia longipalpis Saliva Drives Interleukin-17-Induced Neutrophil Recruitment Favoring Leishmania infantum Infection.

Authors:  Clarissa R Teixeira; Claire da S Santos; Deboraci B Prates; Rafael T Dos Santos; Théo Araújo-Santos; Sebastião M de Souza-Neto; Valéria M Borges; Manoel Barral-Netto; Cláudia I Brodskyn
Journal:  Front Microbiol       Date:  2018-05-08       Impact factor: 5.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.